Plasmodium vivax Vaccine Candidates: Molecular Targets and Challenges in Vaccine Development

Abstract

Plasmodium vivax is a major source of malaria morbidity outside of Africa, posing unique problems for vaccine development due to its complex biology, which includes latent liver-stage hypnozoites that promote recurrent infections. P. vivax, on the other hand, has many distinct antigens, spreads fast, and cannot be grown in vitro, making vaccine development problematic. This analysis provides a comprehensive overview of the top P. vivax vaccine candidates at all phases, including pre-erythrocytic, erythrocytic, and transmission-blocking. It includes important antigens like circumsporozoite protein (CSP), thrombospondin-related adhesive protein (TRAP), Duffy binding protein (DBP), merozoite surface protein-1 (MSP-1), and transmission-blocking targets like Pvs25, Pvs28, Pvs230, and Pvs47. We discuss important issues such as antigenic polymorphism, the lack of correlates of protection, and the difficulty of targeting hypnozoites. Recent advances in vaccination stages, such as mRNA-based technologies, viral vectors, and multi-stage immunization techniques, hold promise for overcoming these challenges. To generate an effective P. vivax vaccine, we must understand more about parasites, develop innovative vaccine designs, and collaborate on a global scale.